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Background: In West and Central Africa Buruli ulcer (BU) and HIV co-infection is increasingly recognised and
management of these two diseases combined is an emerging challenge for which there is little published information.
In this case we present a severe paradoxical reaction occurring after commencing antibiotic treatment for BU combined
with antiretroviral therapy for HIV, and describe its clinical features and management. This includes to our knowledge the
first reported use of prednisolone in Africa to manage a severe paradoxical reaction related to BU treatment.
Case presentation: A 30 year old immunosuppressed HIV positive man from Cameroon developed a severe paradoxical
reaction 24 days after commencing antibiotic treatment for BU and 14 days after commencing antiretroviral therapy for
HIV. Oral prednisolone was successfully used to settle the reaction and prevent further tissue loss. The antiretroviral
regimen was continued unchanged and the BU antibiotic treatment not prolonged beyond the recommended duration
of 8 weeks. A second small local paradoxical lesion developed 8 months after starting antibiotics and settled with
conservative treatment only. Complete healing of lesions occurred and there was no disease recurrence 12 months after
commencement of treatment.
Conclusions: Clinicians should be aware that severe paradoxical reactions can occur during the treatment of BU/HIV
co-infected patients. Prednisolone was effectively and safely used to settle the reaction and minimize the secondary
tissue damage.
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Mycobacterium ulcerans causes severe destructive le-
sions of skin, soft-tissue and bone mediated through its
potent exotoxin mycolactone that are known as Buruli
ulcers (BU). They are most commonly found in Central
and West Africa but have been reported from Australia,
Asia, South America and the Pacific [1]. It predomin-
antly affects children in rural and remote regions and
often results in permanent disability. Co-infection with
HIV is increasingly recognised and is thought to result in
more severe disease and slower healing times following* Correspondence: daniel.obrien@amsterdam.msf.org
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unless otherwise stated.treatment [2-4]. Paradoxical reactions have recently been
recognised to complicate up to 20% of patients receiving
antibiotics for BU, [5] and can lead to significant second-
ary tissue destruction [6]. Prednisolone has been used to
successfully minimize tissue destruction from severe para-
doxical reactions in Australia, [7] but its use in Africa for
this indication has not been reported. It is not known
whether the incidence of paradoxical reactions is affected
by BU/HIV co-infection or antiretroviral treatment (ART),
and there is a lack of information to guide their manage-
ment in BU/HIV co-infected patients [8].
In this case we present a severe paradoxical reaction
occurring in a patient co-infected with BU/HIV after
commencing antibiotic treatment for BU concomitantly
with ART for HIV. We describe its clinical features andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 BU ulcer on lateral aspect of the left ankle complicated
by a severe paradoxical reaction with extending necrosis and
swelling of skin and subcutaneous tissue of the forefoot.
Figure 2 Biopsy of oedematous forefoot lesion 2 weeks after
commencing ART showing a dense inflammatory reaction with
lymphoid granulomas consistent with a paradoxical reaction.
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ported use of prednisolone to manage a severe paradox-
ical reaction related to BU treatment in Africa.
Case presentation
Case details
A 30 year old man living in rural Cameroon presented
to the Buruli ulcer treatment center in Akonolinga,
Cameroon, in January 2013 with a 7-month history of
plaque-like lesions over the lateral aspect of this left
ankle and posterior aspect of his left leg both of which
later ulcerated. The ulcer on the lateral aspect of the left
ankle measured 14 cm x 9 cm with some small areas of
necrosis and inflammation in the surrounding tissue.
The second ulcerative lesion on the left leg measured
6 cm x 4 cm with minimal surrounding inflammation.
Xrays of the left ankle and left leg revealed no evidence
of osteomyelitis deep to the lesions. His weight was
65 kg and Body Mass Index 25. Further examination
was unremarkable with specifically no clinical evidence
of co-infection with tuberculosis and a chest X-ray was
normal.
He had been previously diagnosed elsewhere with HIV
infection and received 2 months of ART from January
2012 but had then interrupted it. A HIV antibody test
on presentation to Akonolinga was positive and a CD4
count was 212 cells/mm3. Baseline viral load was not
available.
The diagnosis of BU was made on the basis of a posi-
tive AFB stain and compatible histopathology showing a
granulomatous infiltrate on tissue biopsies, and a posi-
tive IS2404 PCR and AFB stain on swab specimens, of
both the ankle and leg lesions.
He was hospitalised and commenced on BU treatment
with oral rifampicin 600 mg daily and intramuscular
streptomycin (STM) 1 gram daily on 9/1/13. Within
24 hours he developed a fever to 39.5 degrees and a gen-
eralised pustular and itchy rash. A diagnosis of a STM
hypersensitivity reaction was made and the STM was re-
placed by clarithromycin 500 mg twice daily. Prednisol-
one 30 mg orally daily was also given for 10 days and
the reaction resolved.
Antiretroviral treatment (ART) was commenced on
19/1/13 with a regimen containing zidovudine, lamivu-
dine and efavirenz. Co-trimoxazole 960 mg/day was also
commenced at the same time. Antibiotic and ART ad-
herence was directly supervised in the hospital.
Two weeks after ART initiation the tissue around the
ulcer became inflamed, with significant oedema extend-
ing across the dorsum of the foot to the toes with evi-
dence of extending necrosis and ulceration from the
wound margins. (Figure 1) A provisional clinical diagno-
sis of a severe paradoxical reaction was made and 2 tis-
sue biopsy specimens were performed for histologicaland microbiological examination; one from the edge of
the lesion and one from the centre of the oedematous
dorsum of the foot. Whilst awaiting the results the pa-
tient was commenced on oral prednisolone (50 mg daily)
with the aim to reduce the severity of the paradoxical re-
action and prevent further ulceration of the tissue on
the dorsum of the foot. Prednisolone was continued at
50 mg daily for 2 weeks then weaned to 30 mg daily for
1 week, then 20 mg daily for 2 weeks and then 10 mg
daily for 2 weeks (total 7 weeks). Albendazole 400 mg
daily for 3 days was given at prednisolone commence-
ment to treat any possible strongyloides co-infection.
ART was continued unchanged.
Histopathological examination of the tissue biopsy re-
vealed diffuse inflammation with lymphoid granulomas
(Figure 2) and was negative on examination for acid fast
bacilli (AFB) consistent with a paradoxical reaction.
Mycobacterial cultures were not performed on the tis-
sue. Following prednisolone treatment the tissue oedema
rapidly settled and no further ulceration of the skin on
Figure 4 BU ulcer on lateral aspect left ankle showing
significant reduction in swelling of skin and subcutaneous
tissue of the forefoot with preservation of tissue following
30 days of prednisolone treatment.
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and 4). The prednisolone treatment was well tolerated.
The BU antibiotics were ceased on 3/3/13 after 53 days
of treatment with no further adverse effects. The ankle
lesion underwent surgical debridement to remove hyper-
granulation tissue on 13/3/13. The skin defect under-
went further surgical debridement and was closed with a
split skin graft on 4/7/2013. The graft healed well (Figure 5).
The patient had excellent adherence to his ART which he
tolerated well. After 6 months of ART the viral load was
undetectable and after 8 months the CD4 count had in-
creased to 416 cells/mm3.
A further 1 cm ulcerated lesion on the retromalleolar
region of the left ankle appeared 8 months after the start
of BU antibiotic treatment. (Figure 6) This was diag-
nosed as a late paradoxical reaction clinically and was
confirmed as such by a biopsy revealing significant in-
flammation with no AFB seen on histology, and myco-
bacterial cultures of a swab of the lesion were negative
despite the PCR of the swab remaining positive. The le-
sion healed 12 weeks later with dressings as the only
treatment.
The patient was discharged from hospital 11 months
after starting antibiotics. Twelve months after complet-
ing antibiotic treatment all the lesions remain healed
with no evidence of BU recurrence.
Discussion of case
We present a case of a severe paradoxical reaction oc-
curring in an HIV-infected patient receiving combined
BU antibiotic treatment and ART. The severity of the re-
action threatened the viability of tissue around the BU
lesion, especially across the dorsum of the left foot. The
diagnosis of a paradoxical reaction was initially based on
a consistent clinical picture where the lesion and sur-
rounding tissue deteriorated after 3 weeks of antibioticsFigure 3 BU ulcer on lateral aspect of the left ankle showing
significant reduction in swelling of skin and subcutaneous
tissue of the forefoot with preservation of tissue following
10 days of prednisolone treatment.[5,6]. This was later supported by the histological ap-
pearances that showed evidence of an intense inflamma-
tory reaction consistent with previous descriptions of
paradoxical reactions [6,9]. Paradoxical reactions, also
known as immune reconstitution reactions, [9] are pro-
posed to result from a reversal of the mycolactone toxin
induced immune-inhibitory state via the antibiotic medi-
ated killing of M. ulcerans organisms allowing an intense
immunological reaction to develop against the persisting
mycobacterial antigens [10,11]. As has been reported in
HIV-negative patients following the completion of anti-
biotics, [12,13] a second paradoxical lesion developed on
the retromalleolar region of the left ankle 6 months after
antibiotics were ceased. Late reactions may account for
up to 24% of paradoxical cases, [6] and this reaction was
likely due to enhanced immune responses to a previously
undetected disease focus.
It is not known whether paradoxical reactions are in-
creased in HIV patients with BU, whether this is influ-
enced by the baseline level of immune suppression or
whether it is further potentiated when the generalised
immune suppressed state is partially reversed by ART.
However it is known that paradoxical reactions are com-
mon in HIV patients commencing ART with a variety ofFigure 5 Healed BU lesion 10 months after commencement of
antibiotics and 2 months post split skin graft.
Figure 6 Second paradoxical lesion developing in retromalleolar
region of left ankle 8 months after commencing BU antibiotic
treatment.
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cryptococcus [15] and Mycobacterium avium complex
[16], and that the rate increases with increasing im-
munosuppression at ART baseline [17]. Furthermore in
TB/HIV co-infection, the incidence of TB associated im-
mune reconstitution disease is increased in those who
commence ART within 30 days of commencing TB
treatment [14]. If these findings can be extrapolated to
BU treatment, then in our case some factors existed that
may have increased the paradoxical reaction risk: the
baseline level of immune suppression was significant
(CD4 220 cells/mm3) and ART was commenced early
(2 weeks) after the start of BU treatment. Furthermore
the good response to his ART with a robust increase in
his CD4 cell count and reduction in viral load to un-
detectable levels may have contributed. A recent report
from Ivory Coast also describes further multifocal BU le-
sions developing in a HIV positive patient with severe
immunosuppression (baseline CD4 count of 51 cells/
mm3) one month after starting both BU antibiotic treat-
ment and ART [18]. Further studies on the incidence
and risk factors for paradoxical reactions during treat-
ment of patients co-infected with BU/HIV are needed to
investigate these issues [8].
Oral prednisolone was used in this patient to settle a
severe paradoxical reaction. We believe it prevented fur-
ther skin and subcutaneous tissue loss on the dorsum of
the foot, which commonly occurs during treatment of
oedematous BU lesions and with severe paradoxical re-
actions [6]. Evidence from the mouse model suggests
that the use of corticosteroids does not increase the risk
of BU treatment failure, [19] and it has been used suc-
cessfully in an Australian setting to minimise damage
from severe paradoxical reactions [6,7,20]. Potential risks
of prednisolone administration in an African setting,
such as worsening TB or disseminated strongyloides in-
fection, were minimised by active screening of the patient
for TB and administration of albendazole at initiation
of prednisolone treatment. The prednisolone was welltolerated and did not result in any adverse effects. The
usual recommended dose is 0.5-1.0 mg/kg daily ta-
pered over 4-8 weeks [21]. Of note, despite the use of
prednisolone, the duration of BU antibiotic treatment
was not prolonged and the antiretroviral regimen was
not ceased or altered and this did not appear to ad-
versely affect outcomes.
This case also illustrates a number of important issues
relevant to the patient co-infected with BU and HIV.
Firstly the patient presented with large, multiple and ul-
cerated lesions consistent with previous reports of more
severe BU disease at presentation in those co-infected
with HIV [2,4]. Secondly, due to a hypersensitivity reac-
tion to streptomycin, the patient was treated with the all
oral antibiotic combination of rifampicin and clarithro-
mycin with good success. Although oral combinations
have been effective in observational studies of HIV nega-
tive patients with BU, [22,23] this case provides preliminary
evidence that they may also be effective in HIV co-infected
patients. Thirdly, although effective and safe in this case,
there are concerns regarding the interaction of clarithro-
mycin and efavirenz that may lead to reduced effectiveness
and increased toxicity of BU treatment [24]. This potential
interaction requires further study.
Conclusions
Severe paradoxical reactions can occur during the anti-
biotic treatment of BU/HIV co-infected patients. Pred-
nisolone was effectively and safely used to settle the
reaction and minimize the secondary tissue damage.
Further study on the incidence, risk factors and manage-
ment of paradoxical reactions in HIV/BU co-infected
populations is needed.
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